Tamoxifen

From Self-sufficiency
Jump to: navigation, search
Tamoxifen
File:Tamoxifen Structural Formulae.png
File:Tamoxifen-3D-balls.png
Systematic (IUPAC) name
(Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethyl-ethanamine
Clinical data
Pregnancy
category
Routes of
administration		 Oral
Legal status
Legal status
Pharmacokinetic data
Metabolism Hepatic (CYP3A4, 2C9 and 2D6)
Biological half-life 5–7 days
Excretion Fecal
Identifiers
CAS Number 10540-29-1
ATC code L02BA01 (WHO)
PubChem CID 5376
DrugBank APRD00123
ChemSpider 2015313
Chemical data
Formula C26H29NO
Molar mass 371.515 g/mol
563.638 g/mol (citrate salt)[[Script error: No such module "String".]]
  (verify)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tamoxifen is an antagonist of the estrogen receptor in breast tissue. In other tissues such as the endometrium, it behaves as an agonist, hence tamoxifen may be characterized as a mixed agonist/antagonist. It has been the standard endocrine (anti-estrogen) therapy for hormone-positive early breast cancer in post-menopausal women, although aromatase inhibitors have been proposed.[1]

Some breast cancer cells require estrogen to grow. Estrogen binds to and activates the estrogen receptor in these cells. Tamoxifen is metabolized into compounds that also bind to the estrogen receptor but do not activate it. Because of this competitive antagonism, tamoxifen acts like a key broken off in the lock that prevents any other key from being inserted, preventing estrogen from binding to its receptor. Hence breast cancer cell growth is blocked.

Tamoxifen was discovered by ICI Pharmaceuticals[2] (now AstraZeneca) and is sold under the trade names Nolvadex, Istubal, and Valodex. However, the drug, even before its patent expiration, was and still is widely referred to by its generic name "tamoxifen."

Breast cancer treatment

File:Tamoxifen cancer drug.jpg
Bottle and pills of tamoxifen

Tamoxifen is currently used for the treatment of both early and advanced ER+ (estrogen receptor positive) breast cancer in pre- and post-menopausal women.[3] Additionally, it is the most common hormone treatment for male breast cancer.[4] It is also approved by the FDA for the prevention of breast cancer in women at high risk of developing the disease.[5] It has been further approved for the reduction of contralateral (in the opposite breast) cancer.

Comparative studies

In 2006, the large STAR clinical study concluded that raloxifene is equally effective in reducing the incidence of breast cancer, but after an average 4-year follow-up there were 36% fewer uterine cancers and 29% fewer blood clots in women taking raloxifene than in women taking tamoxifen, although the difference is not statistically significant.[6][7][8]

In 2005, the ATAC trial showed that after average 68 months following a 5 year adjuvant treatment, the group that received anastrozole (Arimidex) had significantly better results than the tamoxifen group in measures like disease free survival, but no overall mortality benefit.[9] Data from the trial suggest that anastrozole should be the preferred medication for postmenopausal women with localized breast cancer that is estrogen receptor (ER) positive.[10] Another study found that the risk of recurrence was reduced 40% (with some risk of bone fracture) and that ER negative patients also benefited from switching to anastrozole.[11][12]

Other uses

Infertility

Tamoxifen is used to treat infertility in women with anovulatory disorders. A dose of 10–40 mg per day is administered in days 3–7 of a woman's cycle.[13] In addition, a rare condition occasionally treated with tamoxifen is retroperitoneal fibrosis.[14]

Gynecomastia

Tamoxifen is used to prevent estrogen related gynecomastia, resulting from elevated estrogenic levels in conjunction with steroid use. It is taken as a preventative measure in small doses, or used at the onset of any symptoms e.g. nipple soreness/sensitivity. Other drugs are taken for the similar purposeses such as clomiphene citrate and the anti-aromatase drugs which are used in order to try to avoid the hormone related adverse effects of steroid use. Tamoxifen is also sometimes used to treat or prevent gynecomastia in sex offenders undergoing treatment by temporary chemical castration.[15]

Bipolar disorder

Tamoxifen has been shown to be effective in the treatment of mania in patients with bipolar disorder by blocking protein kinase C (PKC), an enzyme that regulates neuron activity in the brain. Researchers believe PKC is over-active during the mania in bipolar patients.[16][17]

Angiogenesis and cancer

Tamoxifen is one of three drugs in an anti-angiogenetic protocol developed by Dr. Judah Folkman, a researcher at Children's Hospital at Harvard Medical School in Boston. Folkman discovered in the 1970s that angiogenesis – the growth of new blood vessels – plays a significant role in the development of cancer. Since his discovery, an entirely new field of cancer research has developed. Clinical trials on angiogenesis inhibitors have been underway since 1992 using a myriad of different drugs. The Harvard researchers developed a specific protocol for a golden retriever named Navy who was cancer-free after receiving the prescribed cocktail of celecoxib, doxycycline, and tamoxifen – the treatment subsequently became known as the Navy Protocol.[18] Furthermore tamoxifen treatment alone has been shown to have anti-angiogenetic effects in animal models of cancer which appear to be, at least in part, independent of tamoxifen's estrogen receptor antagonist properties.[19]

Control of gene expression

Tamoxifen is used as a research tool to trigger tissue specific gene expression in many conditional expression constructs in genetically modified animals including a version of the Cre-Lox recombination technique.[20]

Mechanism of action

File:3ert.png
X-ray crystal structure (PDB 3ERT) of 4-hydroxytamoxifen (white sticks) complexed with the ligand binding domain of the estrogen receptor (cyan cartoon diagram).

Tamoxifen competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects. It is a nonsteroidal agent with potent antiestrogenic properties which compete with estrogen for binding sites in breast and other tissues. Tamoxifen causes cells to remain in the G0 and G1 phases of the cell cycle. Because it prevents (pre)cancerous cells from dividing but does not cause cell death, tamoxifen is cytostatic rather than cytocidal.

Tamoxifen itself is a prodrug, having relatively little affinity for its target protein, the estrogen receptor. It is metabolized in the liver by the cytochrome P450 isoform CYP2D6 and CYP3A4 into active metabolites such as 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen (endoxifen)[21] which have 30-100 times more affinity with the estrogen receptor than tamoxifen itself. These active metabolites compete with estrogen in the body for binding to the estrogen receptor. In breast tissue, 4-hydroxytamoxifen acts as an estrogen receptor antagonist so that transcription of estrogen-responsive genes is inhibited.[22]

Tamoxifen binds to estrogen receptor (ER) which in turn interacts with DNA. The ER/tamoxifen complex recruits other proteins known as co-repressors to stop genes being switched on by estrogen. Some of these proteins include NCoR and SMRT.[23] Tamoxifen function can be regulated by a number of different variables including growth factors.[24] Tamoxifen needs to block growth factor proteins such as ErbB2/HER2[25] because high levels of ErbB2 have been shown to occur in tamoxifen resistant cancers.[26] Tamoxifen seems to require a protein PAX2 for its full anticancer effect.[25][27] In the presence of high PAX2 expression, the tamoxifen/estrogen receptor complex is able to suppress the expression of the pro-proliferative ERBB2 protein. In contrast, when AIB-1 expression is higher than PAX2, tamoxifen/estrogen receptor complex upregulates the expression of ERBB2 resulting in stimulation of breast cancer growth.[25][28]

Side effects

A report in September 2009 from Health and Human Services' Agency for Healthcare Research and Quality suggests that tamoxifen, raloxifene, and tibolone used to treat breast cancer significantly reduce invasive breast cancer in midlife and older women, but also increase the risk of adverse side effects.[29]

Bone

A beneficial side effect of tamoxifen is that it prevents bone loss by acting as an estrogen receptor agonist (i.e., mimicking the effects of estrogen) in this cell type. Therefore, by inhibiting osteoclasts, it prevents osteoporosis.[30][31] When tamoxifen was launched as a drug, it was thought that tamoxifen would act as an estrogen receptor antagonist in all tissue, including bone, and therefore it was feared that it would contribute to osteoporosis. It was therefore very surprising that the opposite effect was observed clinically. Hence tamoxifen's tissue selective action directly led to the formulation of the concept of selective estrogen receptor modulators (SERMs).[32] In contrast tamoxifen appears to be associated with bone loss in premenopausal women who continue to menstruate after adjuvant chemotherapy.[33]

Endometrial cancer

Tamoxifen is a selective estrogen receptor modulator.[34] Even though it is an antagonist in breast tissue it acts as partial agonist on the endometrium and has been linked to endometrial cancer in some women. Therefore endometrial changes, including cancer, are among tamoxifen's side effects.[35] With time, risk of endometrial cancer may be doubled to quadrupled, which is a reason tamoxifen is typically only used for 5 years.[36]

The American Cancer Society lists tamoxifen as a known carcinogen, stating that it increases the risk of some types of uterine cancer while lowering the risk of breast cancer recurrence.[37] The ACS states that its use should not be avoided in cases where the risk of breast cancer recurrence without the drug is higher than the risk of developing uterine cancer with the drug.

Cardiovascular and metabolic

Tamoxifen treatment of postmenopausal women is associated with beneficial effects on serum lipid profiles. However, long-term data from clinical trials have failed to demonstrate a cardioprotective effect.[38] For some women, tamoxifen can cause a rapid increase in triglyceride concentration in the blood.[citation needed] In addition there is an increased risk of thromboembolism especially during and immediately after major surgery or periods of immobility.[39] Tamoxifen is also a cause of fatty liver, otherwise known as steatorrhoeic hepatosis or steatosis hepatis.[40]

Central nervous system

Tamoxifen treated breast cancer patients show evidence of reduced cognition[41] and semantic memory scores.[42] However memory impairment in patients treated with tamoxifen was less severe compared with those treated with anastrozole (an aromatase inhibitor).[43]

A significant number of tamoxifen treated breast cancer patients experience a reduction of libido.[44][45]

Pre-mature growth plate fusion

While tamoxifen has been shown to antagonize the actions of estrogen in tissues such as the breast, its effects in other tissues such as bones has not been documented fully. There have been studies done in mice showing tamoxifen mimic the effects of estrogen on bone metabolism and skeletal growth. Thus increasing the possibility of pre-mature bone fusion. This effect would be less of a concern in adults who have stopped growing.[46]

Pharmacogenetics and drug interactions

Patients with variant forms of the gene CYP2D6 (also called simply 2D6) may not receive full benefit from tamoxifen because of too slow metabolism of the tamoxifen prodrug into its active metabolite 4-hydroxytamoxifen.[47][48] On Oct 18, 2006 the Subcommittee for Clinical Pharmacology recommended relabeling tamoxifen to include information about this gene in the package insert.[49]

Certain CYP2D6 variations in breast cancer patients leads to a worse clinical outcome for tamoxifen treatment.[50] Genotyping therefore has the potential for identification of women who have these CYP2D6 phenotypes and for whom the use of tamoxifen is associated with poor outcomes.

Recent studies suggest that taking selective serotonin reuptake inhibitor (SSRI) antidepressants such as Paxil, Prozac, etc., can decrease the effectiveness of tamoxifen, because these drugs compete for the CYP2D6 enzyme which is needed to metabolize tamoxifen into the active form endoxifen.[51] A U.S study presented at the American Society of Clinical Oncology's annual meeting in 2009 found that after two years, 7.5 percent of women who took only tamoxifen had a recurrence, compared with 16 percent who took Paxil, Prozac, or Zoloft—drugs considered to be the most potent CYP2D6 inhibitors. That difference translates to a 120 percent increase in the risk of breast cancer recurrence. Patients taking the so-called weaker antidepressants, Celexa (citalopram), Lexapro (escitalopram), and Luvox (fluvoxamine), did not have an increased risk of recurrence.[52] A newer study showed a clearer and stronger effect paroxetine causing worse outcomes. Patients treated with both paroxetine and tamoxifen have an increased risk of death from breast cancer from 24% to 91%, depending on duration of coexposure. [53]

Recent research has shown that 7-10% of women with breast cancer may not receive the full medical benefit from taking tamoxifen due to their unique genetic make-up. DNA Drug Safety Testing can examine DNA variations in the CYP2D6 and other important drug processing pathways. More than 20% of all clinically used medications are metabolized by CYP2D6 and knowing the CYP2D6 status of a person can help the doctor with the future selection of medications.[54]

Market

Global sales of tamoxifen in 2001 were $1,024 million.[55] Since the expiration of the patent in 2002, it is now widely available as a generic drug around the world. Barr Labs Inc had challenged the patent (which in 1992 was ruled unenforcable) but later came to an agreement with Zeneca to licence the patent and sell tamoxifen at close to Zeneca's price.[56] As of 2004, tamoxifen was the world's largest selling hormonal drug for the treatment of breast cancer.[57]

In the US, 20 mg tamoxifen tablets cost under $20 per month in quantity.[58] In the UK, the NHS pays £1.90 a month (patients receive them either free or for the standard prescription charge of £7.10 in England, £4 in Scotland[59], £3 in Northern Ireland[60] and free in Wales). In Estonia tamoxifen costs less than $2 for 30 tablets of 20mg when used for treatment of a neoplasm or lymphangioma.[61] Other countries report similar prices.[citation needed]

Discovery

In the late 1950s, pharmaceutical companies were actively researching a newly discovered class of anti-estrogen compounds in the hope of developing a morning-after contraceptive pill. Arthur L Walpole was a reproductive endocrinologist who led such a team at the Alderley Park research laboratories of ICI Pharmaceuticals. It was there in 1962 that Dora Richardson first synthesised tamoxifen, known then as ICI-46,474.[62] Walpole and his colleagues filed a UK patent covering this compound in 1962, but patent protection on this compound was repeatedly denied in the US until the 1980s.[63] Tamoxifen did eventually receive marketing approval as a fertility treatment, but the class of compounds never proved useful in human contraception. A link between estrogen and breast cancer had been known for many years, but cancer treatments were not a corporate priority at the time, and Walpole's personal interests were important in keeping support for the compound alive in the face of this and the lack of patent protection.[2]

The first clinical study took place at the Christie Hospital in 1971, and showed a convincing effect in advanced breast cancer,[64] but nevertheless ICI's development programme came close to termination when it was reviewed in 1972. Tamoxifen's further development may have been bolstered by a second clinical study by Harold W.C. Ward [65] at the Queen Elizabeth Hospital, Birmingham. Ward's study showed a more definitive response to the drug at a higher dosage. It appears to have been Walpole again who convinced the company to market tamoxifen for late stage breast cancer in 1973.[63] He was also instrumental in funding V. Craig Jordan to work on tamoxifen. Approval in the US followed in 1977, but the drug was competing against other hormonal agents in a relatively small marketplace and was not at this stage either clinically or financially remarkable.

1980 saw the publication of the first trial to show that tamoxifen given in addition to chemotherapy improved survival for patients with early breast cancer.[66] In advanced disease, tamoxifen is now only recognised as effective in estrogen receptor positive (ER+) patients, but the early trials did not select ER+ patients, and by the mid 1980s the clinical trial picture was not showing a major advantage for tamoxifen.[67] Nevertheless, tamoxifen had a relatively mild side-effect profile, and a number of large trials continued. It was not until 1998 that the meta-analysis of the Oxford based Early Breast Cancer Trialists' Collaborative Group showed definitively that tamoxifen saved lives in early breast cancer.[68]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

Estrogens and progestogens (G03C-D, L02)
Progestogens/
progestins
(progesterone)
Agonist
Other/
ungrouped
Estrogens
Agonist
de:Tamoxifen

es:Tamoxifeno fa:تاموکسیفن fr:Tamoxifène it:Tamoxifene he:טמוקסיפן nl:Tamoxifen ja:タモキシフェン pl:Tamoksyfen

pt:Tamoxifeno
  1. ↑ Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer, The BIG 1-98 Collaborative Group, N Engl J Med, 361:766 Aug. 20, 2009
  2. ↑ 2.0 2.1 Jordan VC (2006). "Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer". Br J Pharmacol. 147 (Suppl 1): S269–76. doi:10.1038/sj.bjp.0706399. PMC 1760730 Freely accessible. PMID 16402113. 
  3. ↑ Jordan VC (1993). "Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer". Br J Pharmacol. 110 (2): 507–17. PMC 2175926 Freely accessible. PMID 8242225. 
  4. ↑ "Breast cancer in men". CancerHelp UK. Cancer Research UK. 2007-09-28. Retrieved 2009-03-22. 
  5. ↑ Center for Drug Evaluation and Research (03/08/2005). "Tamoxifen Information: reducing the incidence of breast cancer in women at high risk". U.S. Food and Drug Administration. Retrieved July 3, 2007.  Check date values in: |date= (help)
  6. ↑ National Cancer Institute (2006-04-26). "Study of Tamoxifen and Raloxifene (STAR) Trial". U.S. National Institutes of Health. Retrieved July 3, 2007. 
  7. ↑ University of Pittsburgh. "STAR Study of Tamoxifen and Raloxifen". Retrieved July 3, 2007. 
  8. ↑ Dr Susan Love (April 22, 2006). "Study Finds New Use for Raloxifene: Reducing Breast Cancer in High-Risk Postmenopausal Women". Retrieved March 19, 2009. 
  9. ↑ "Tamoxifen vs Arimidex as Adjuvant Therapy | Health and Life
  10. ↑ Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS (2005). "Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer". Lancet. 365 (9453): 60–2. doi:10.1016/S0140-6736(04)17666-6. PMID 15639680. 
  11. ↑ "Arimidex After Two Years of Tamoxifen Reduces Recurrence in Post-Menopausal Women". BreastCancer.org. Retrieved 2008-11-14. 
  12. ↑ Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG (2005). "Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial". Lancet. 366 (9484): 455–62. doi:10.1016/S0140-6736(05)67059-6. PMID 16084253. 
  13. ↑ Steiner AZ, Terplan M, Paulson RJ (2005). "Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis". Hum. Reprod. 20 (6): 1511–5. doi:10.1093/humrep/deh840. PMID 15845599. 
  14. ↑ van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG (2006). "Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis". Ann. Intern. Med. 144 (2): 101–6. PMID 16418409. 
  15. ↑ Sample, Ian (2007-06-13). "Q&A: Chemical castration". Guardian Unlimited. Retrieved 2007-09-10. 
  16. ↑ "Manic Phase of Bipolar Disorder Benefits from Breast Cancer Medication". National Institutes of Mental Health. September 12, 2007. Retrieved 2008-03-10. 
  17. ↑ Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF (2008). "Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen". Arch. Gen. Psychiatry. 65 (3): 255–63. doi:10.1001/archgenpsychiatry.2007.43. PMID 18316672. 
  18. ↑ Kirk E (2002-07-24). "Dog's tale of survival opens door in cancer research". Health and Behavior. USA Today. Retrieved 2008-06-24. 
  19. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  20. ↑ Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P (1996). "Ligand-activated site-specific recombination in mice". Proc. Natl. Acad. Sci. U.S.A. 93 (20): 10887–90. doi:10.1073/pnas.93.20.10887. PMC 38252 Freely accessible. PMID 8855277. 
  21. ↑ Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004). "Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6". J Pharmacol Exp Ther. 310 (3): 1062–75. doi:10.1124/jpet.104.065607. PMID 15159443. 
  22. ↑ Wang DY, Fulthorpe R, Liss SN, Edwards EA (2004). "Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1". Mol Endocrinol. 18 (2): 402–11. doi:10.1210/me.2003-0202. PMID 14605097. 
  23. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  24. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  25. ↑ 25.0 25.1 25.2 Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  26. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  27. ↑ "New Mechanism Predicts Tamoxifen Response: PAX2 gene implicated in tamoxifen-induced inhibition of ERBB2/HER2-mediated tumor growth". www.modernmedicine.com. 2008-11-13. Retrieved 2008-11-14. 
  28. ↑ "Study sheds new light on tamoxifen resistance". News. CORDIS News. Retrieved 2008-11-14. 
  29. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  30. ↑ Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S (2007). "Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts". Cell. 130 (5): 811–23. doi:10.1016/j.cell.2007.07.025. PMID 17803905. 
  31. ↑ Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M (2008). "Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival". EMBO J. 27 (3): 535–45. doi:10.1038/sj.emboj.7601984. PMC 2241656 Freely accessible. PMID 18219273. 
  32. ↑ Mincey BA, Moraghan TJ, Perez EA (2000). "Prevention and treatment of osteoporosis in women with breast cancer" ([dead link] – Scholar search). Mayo Clin Proc. 75 (8): 821–9. doi:10.4065/75.8.821. PMID 10943237. 
  33. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  34. ↑ Gallo MA, Kaufman D (1997). "Antagonistic and agonistic effects of tamoxifen: significance in human cancer". Semin Oncol. 24 (Suppl 1): S1–71–S1–80. PMID 9045319. 
  35. ↑ Grilli S (2006). "Tamoxifen (TAM): the dispute goes on" (PDF). Ann Ist Super Sanita. 42 (2): 170–3. PMID 17033137. 
  36. ↑ "Tamoxifen for Breast Cancer & Side Effects". Health and Life. 
  37. ↑ "Known and Probable Carcinogens". American Cancer Society. 2006-02-03. Retrieved 2008-03-21. 
  38. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  39. ↑ Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U (2005). "Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial". Circulation. 111 (5): 650–6. doi:10.1161/01.CIR.0000154545.84124.AC. PMID 15699284. 
  40. ↑ Khalid A Osman; Meissa M Osman; Mohamed H Ahmed (2007). "Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?". Expert opinion on drug safety. 6 (1): 1–4. doi:10.1517/14740338.6.1.1. PMID 17181445. 
  41. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  42. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  43. ↑ Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL (2007). "Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer". Menopause (New York, N.Y.). 14 (6): 995–8. doi:10.1097/gme.0b013e318148b28b. PMC 2831410 Freely accessible. PMID 17898668. 
  44. ↑ Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH (1999). "Effect of tamoxifen on sexual functioning in patients with breast cancer" (abstract). J. Clin. Oncol. 17 (5): 1488–92. PMID 10334535. 
  45. ↑ Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A (2006). "Quality of life of post-menopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer". Breast Cancer Res. Treat. 100 (3): 273–84. doi:10.1007/s10549-006-9260-6. PMID 16944295. 
  46. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  47. ↑ Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005). "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes". J Clin Oncol. 23 (36): 9312–8. doi:10.1200/JCO.2005.03.3266. PMID 16361630. 
  48. ↑ Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD (2007). "CYP2D6 polymorphisms and the impact on tamoxifen therapy". J Pharm Sci. 96 (9): Epub ahead of print. doi:10.1002/jps.20892. PMID 17518364. 
  49. ↑ Information about CYP2D6 and tamoxifen from DNADirect's website
  50. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  51. ↑ Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005). "CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment". J Natl Cancer Inst. 97 (1): 30–9. doi:10.1093/jnci/dji005. PMID 15632378. 
  52. ↑ Staff Reports (Summer, 2009). "ASCO Updates: Antidepressants Reduce the Effectiveness of Tamoxifen". CURE (Cancer Updates, Research and Education).  Check date values in: |date= (help)
  53. ↑ BMJ 2010;340:c693
  54. ↑ Information about Tamoxitest and how DNA testing can help in the selection of the best treatment methodology from Genelex's website
  55. ↑ "Cancer the generic impact". BioPortfolio Limited. Retrieved 2008-11-14. 
  56. ↑ "Tamoxifen". Lawsuits & Settlements. Prescription Access Litigation. Retrieved 2008-11-14. 
  57. ↑ Vose B. "AstraZenecain Cancer: Slide #15:" (PDF). AstraZeneca Annual Business Review. www.astrazeneca.com. Retrieved 2009-03-28. 2004 tamoxifen market share: 70% Source: IMS HEALTH, IMS MIDAS Monthly. July 2004. Aromatase Inhibitors + Tamoxifen 
  58. ↑ Drugstore.com accessed on 21 August 2009
  59. ↑ http://www.scotland.gov.uk/News/Releases/2007/12/05141211
  60. ↑ http://www.northernireland.gov.uk/news/news-dhssps/news-dhssps-december-2008/news-dhssps-301208-prescription-charges-reduced.htm
  61. ↑ http://www.raviminfo.ee/apthkiri.php?apteek=?&regioon=01&atc=L02BA01
  62. ↑ Sneader, Walter (2005). Drug discovery: a history. New York: Wiley. p. 472 pages. ISBN 0-471-89979-8. 
  63. ↑ 63.0 63.1 Jordan VC (2003). "Tamoxifen: a most unlikely pioneering medicine". Nature reviews. Drug discovery. 2 (3): 205–13. doi:10.1038/nrd1031. PMID 12612646. 
  64. ↑ Cole MP, Jones CT, Todd ID (1971). "A new anti-estrogenic agent in late breast cancer. An early clinical appraisal of ICI46474". Br. J. Cancer. 25 (2): 270–5. PMC 2008453 Freely accessible. PMID 5115829. 
  65. ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  66. ↑ Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC, Richards D, Ellis SH (1983). "Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer". Lancet. 2 (8347): 450. doi:10.1016/S0140-6736(83)90406-3. PMID 6135926. 
  67. ↑ Furr BJ, Jordan VC (1984). "The pharmacology and clinical uses of tamoxifen". Pharmacol. Ther. 25 (2): 127–205. doi:10.1016/0163-7258(84)90043-3. PMID 6438654. 
  68. ↑ Early Breast Cancer Trialists' Collaborative Group (1998). "Tamoxifen for early breast cancer: an overview of the randomised trials". Lancet. 351 (9114): 1451–67. doi:10.1016/S0140-6736(97)11423-4. PMID 9605801. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Tamoxifen&oldid=18651"